Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Amylyx Pharmaceuticals (AMLX) Cost of Revenue (2022 - 2024)

Amylyx Pharmaceuticals has reported Cost of Revenue over the past 3 years, most recently at $8000.0 for Q2 2024.

  • Quarterly results put Cost of Revenue at $8000.0 for Q2 2024, down 99.86% from a year ago — trailing twelve months through Mar 2025 was $8000.0 (down 99.97% YoY), and the annual figure for FY2024 was $6.0 million, down 76.6%.
  • Cost of Revenue for Q2 2024 was $8000.0 at Amylyx Pharmaceuticals, down from $5.9 million in the prior quarter.
  • Over the last five years, Cost of Revenue for AMLX hit a ceiling of $9.4 million in Q4 2023 and a floor of $8000.0 in Q2 2024.
  • Median Cost of Revenue over the past 3 years was $5.3 million (2023), compared with a mean of $4.3 million.
  • Biggest five-year swings in Cost of Revenue: surged 2933.72% in 2023 and later plummeted 99.86% in 2024.
  • Amylyx Pharmaceuticals' Cost of Revenue stood at $2.8 million in 2022, then skyrocketed by 231.8% to $9.4 million in 2023, then tumbled by 99.91% to $8000.0 in 2024.
  • The last three reported values for Cost of Revenue were $8000.0 (Q2 2024), $5.9 million (Q1 2024), and $9.4 million (Q4 2023) per Business Quant data.